Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
2013
efit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. Conclusions In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Phar -
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
2047
Citations
NaN
KQI